JP2010500284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500284A5 JP2010500284A5 JP2009515468A JP2009515468A JP2010500284A5 JP 2010500284 A5 JP2010500284 A5 JP 2010500284A5 JP 2009515468 A JP2009515468 A JP 2009515468A JP 2009515468 A JP2009515468 A JP 2009515468A JP 2010500284 A5 JP2010500284 A5 JP 2010500284A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mammals
- humans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 CCCC(C1C(/C(/C=*/CC2C)=C/C=C2/C(F)(F)F)=O)C1(C)/C(/C(C)C/C(/C)=C1)=C/C=C1\c1nc(N(CCC)C(N(C2CC2)C2=O)=O)c2[n]1C1CCC1 Chemical compound CCCC(C1C(/C(/C=*/CC2C)=C/C=C2/C(F)(F)F)=O)C1(C)/C(/C(C)C/C(/C)=C1)=C/C=C1\c1nc(N(CCC)C(N(C2CC2)C2=O)=O)c2[n]1C1CCC1 0.000 description 2
- SHWCLAKWPQCZNV-UHFFFAOYSA-N CCCN(c1c(C(N2C3CC3)=O)[nH]c(-c(cc3)cnc3N(CC)C(c3ccc(C(F)(F)F)nc3)=N)n1)C2=O Chemical compound CCCN(c1c(C(N2C3CC3)=O)[nH]c(-c(cc3)cnc3N(CC)C(c3ccc(C(F)(F)F)nc3)=N)n1)C2=O SHWCLAKWPQCZNV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80503006P | 2006-06-16 | 2006-06-16 | |
| US60/805,030 | 2006-06-16 | ||
| US80556406P | 2006-06-22 | 2006-06-22 | |
| US60/805,864 | 2006-06-22 | ||
| US11/811,823 US7884100B2 (en) | 2006-06-16 | 2007-06-12 | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US11/811,823 | 2007-06-12 | ||
| PCT/US2007/013849 WO2007149277A2 (en) | 2006-06-16 | 2007-06-13 | Substituted 8-[6-amino-3-pyridyl]xanthines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500284A JP2010500284A (ja) | 2010-01-07 |
| JP2010500284A5 true JP2010500284A5 (cg-RX-API-DMAC7.html) | 2010-07-22 |
| JP5417558B2 JP5417558B2 (ja) | 2014-02-19 |
Family
ID=56290980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515468A Expired - Fee Related JP5417558B2 (ja) | 2006-06-16 | 2007-06-13 | 置換８−［６−アミノ−３−ピリジル］キサンチン類 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7884100B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2029143B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5417558B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101413404B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103145712A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007261568B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0712001B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2655598C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2029143T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA016791B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2548437T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE026457T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL195916A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008015954A (cg-RX-API-DMAC7.html) |
| MY (1) | MY152178A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ597222A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2029143T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2029143E (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| US7598379B2 (en) | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| BR112023023996A2 (pt) * | 2021-05-18 | 2024-01-30 | Adovate Llc | Xantinas de piridil contendo amida cíclica como antagonistas de a2b |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6060481A (en) * | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
| GB9817623D0 (en) * | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| AU2001238342A1 (en) * | 2000-02-17 | 2001-08-27 | Cv Therapeutics, Inc. | Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| KR100937620B1 (ko) * | 2001-11-09 | 2010-01-20 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제 |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| NZ528591A (en) * | 2002-02-01 | 2006-11-30 | King Pharmaceuticals Res & Dev | 8-heteroaryl xanthine adenosine A2B receptor antagonists and their pharmaceutical use |
| US7034070B2 (en) * | 2002-09-27 | 2006-04-25 | Vincent Chuang | Arylalkyl aminofunctional silanes for epoxy laminates |
| US7148229B2 (en) * | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| KR101247528B1 (ko) | 2004-09-01 | 2013-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제를 사용하는 상처 치유 방법 |
| WO2006028840A2 (en) | 2004-09-03 | 2006-03-16 | United States Postal Service | Methods and systems for providing an enterprise supply management portal |
| CN101039677A (zh) * | 2004-10-15 | 2007-09-19 | Cv医药有限公司 | 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法 |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| US7598379B2 (en) * | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
| US7625881B2 (en) * | 2005-06-16 | 2009-12-01 | Gilead Palo Alto, Inc. | Prodrugs of A2B adenosine receptor antagonists |
| JP5250848B2 (ja) * | 2006-03-17 | 2013-07-31 | ギリアード サイエンシーズ， インコーポレイテッド | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
| AU2006344750A1 (en) * | 2006-06-15 | 2007-12-27 | Targeted Genetics Corporation | Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| CA2718983C (en) * | 2008-03-26 | 2015-12-08 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
-
2007
- 2007-06-12 US US11/811,823 patent/US7884100B2/en not_active Expired - Fee Related
- 2007-06-13 KR KR1020097000879A patent/KR101413404B1/ko active Active
- 2007-06-13 NZ NZ597222A patent/NZ597222A/xx unknown
- 2007-06-13 MX MX2008015954A patent/MX2008015954A/es active IP Right Grant
- 2007-06-13 AU AU2007261568A patent/AU2007261568B2/en active Active
- 2007-06-13 PT PT77960490T patent/PT2029143E/pt unknown
- 2007-06-13 PL PL07796049T patent/PL2029143T3/pl unknown
- 2007-06-13 ES ES07796049.0T patent/ES2548437T3/es active Active
- 2007-06-13 JP JP2009515468A patent/JP5417558B2/ja not_active Expired - Fee Related
- 2007-06-13 EP EP07796049.0A patent/EP2029143B1/en active Active
- 2007-06-13 BR BRPI0712001A patent/BRPI0712001B8/pt active IP Right Grant
- 2007-06-13 MY MYPI20084937 patent/MY152178A/en unknown
- 2007-06-13 CA CA2655598A patent/CA2655598C/en active Active
- 2007-06-13 CN CN2013100513402A patent/CN103145712A/zh active Pending
- 2007-06-13 HU HUE07796049A patent/HUE026457T2/en unknown
- 2007-06-13 EA EA200900010A patent/EA016791B1/ru unknown
- 2007-06-13 DK DK07796049.0T patent/DK2029143T3/en active
-
2008
- 2008-12-14 IL IL195916A patent/IL195916A/en active IP Right Grant
-
2010
- 2010-12-14 US US12/967,876 patent/US8258142B2/en active Active